MedTrace Logo

Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2026 and 2029.

NCT07325851 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2026-01-08

No results posted yet for this study

Summary

The main objective of this study is to analyze the impact on the health-related quality of life of patients with refractory symptoms who have been referred to the Dr. Negrín University Hospital Chronic Pain Unit for adjuvant palliative treatment with ozone therapy between January 2026 and December 2029. Additionally, the study aims to evaluate several specific symptoms, hyperspectral and thermal images, non-invasive clinical parameters related to the Autonomic Nervous System (such as heart rate variability, electrochemical skin conductance, and vibration perception thresholds), oxidative stress and inflammatory parameters, and gut microbiota composition.

Conditions

  • Chemotherapy-Induced Peripheral Neuropathy
  • Radiation Toxicity
  • Chronic Pain
  • Delayed Wound Healing
  • Refractory Symptoms

Interventions

PROCEDURE

Ozone Therapy

Systemic (rectal, autohemotherapy) and/or local ozone administration (cutaneous, intravaginal, intravesical). Dosage, frequency, and duration will depend on the symptoms treated and clinical evolution. Usually planned 40 sessions over 4 months.

Sponsors & Collaborators

  • Dr. Negrin University Hospital

    collaborator OTHER

  • Fundacion Canaria Instituto de Investigacion Sanitaria de Canarias

    collaborator OTHER

  • Complejo Hospitalario Universitario Insular Materno Infantil (CHUIMI)

    collaborator UNKNOWN

  • Instituto Universitario de Microelectrónica Aplicada de la Universidad de Las Palmas de Gran Canaria (IUMA-ULPGC)

    collaborator UNKNOWN

  • Council of Gran Canaria

    collaborator OTHER

  • Bernardino Clavo, MD, PhD

    lead OTHER

Principal Investigators

  • Bernardino Clavo, MD, PhD · Dr. Negrín University Hospital, Las Palmas, Spain

  • Francisco Rodríguez-Esparragón, BSc, PhyD · Dr. Negrín University Hospital, Las Palmas, Spain

  • Ángeles Cánovas-Molina, RN · Dr. Negrín University Hospital, Las Palmas, Spain

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-14
Primary Completion
2029-12-31
Completion
2030-06-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07325851 on ClinicalTrials.gov